Vir Biotechnology Quarterly Balance Sheet
NASDAQ: VIRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 11.92 +1.88%
Vir Biotechnology financial position
As of Jun 30, 2026, Vir Biotechnology reported total assets of $1.21 billion, up 1.9% from a year earlier against total liabilities of $232.3 million. Shareholders' equity stood at $982.5 million, or 80.9% of assets. The company held $278.7 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 6.04, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Vir Biotechnology balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 278.73M | 274.16M | 232.19M | 170.08M | 211.10M | 273.57M | 222.95M | 168.35M | 296.86M | 160.71M | 241.58M | 452.10M |
| Short-Term Investments | 249.86M | 196.28M | 228.75M | 327.75M | 387.64M | 517.37M | 678.05M | 740.61M | 849.83M | 985.13M | 1.27B | 1.23B |
| Total Current Assets | 573.74M | 522.99M | 514.08M | 545.68M | 735.71M | 932.21M | 1.04B | 1.05B | 1.21B | 1.21B | 1.59B | 1.77B |
| Property, Plant & Equipment | 50.43M | 53.16M | 55.62M | 58.20M | 60.80M | 61.68M | 63.18M | 64.79M | 66.06M | 92.48M | 96.02M | 99.31M |
| Goodwill | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M |
| Intangible Assets | 7.70M | 7.78M | 7.85M | 7.92M | 8.00M | 8.07M | 8.12M | 19.26M | 18.90M | 22.46M | 22.57M | 25.46M |
| Long-Term Investments | 475.02M | 332.97M | 314.57M | 304.21M | 286.10M | 218.14M | 190.01M | 271.50M | 279.99M | 359.72M | 105.28M | 39.62M |
| Total Assets | 1.21B | 1.03B | 1.00B | 1.02B | 1.19B | 1.31B | 1.40B | 1.50B | 1.67B | 1.79B | 1.92B | 2.04B |
| Accounts Payable | 17.75M | 5.45M | 9.80M | 6.85M | 12.23M | 3.73M | 5.08M | 7.30M | 4.39M | 7.11M | 6.33M | 3.63M |
| Total Current Liabilities | 94.96M | 73.56M | 92.81M | 75.22M | 105.00M | 137.29M | 119.66M | 117.16M | 96.41M | 94.07M | 175.41M | 165.05M |
| Total Liabilities | 232.31M | 212.82M | 237.55M | 223.35M | 245.06M | 263.91M | 248.43M | 257.63M | 235.88M | 246.61M | 328.82M | 369.81M |
| Shareholders' Equity | 982.49M | 812.76M | 765.28M | 796.10M | 947.47M | 1.04B | 1.15B | 1.24B | 1.43B | 1.55B | 1.59B | 1.68B |
| Retained Earnings | -1.24B | -1.32B | -1.20B | -1.15B | -991.71M | -880.75M | -759.78M | -655.20M | -441.48M | -303.10M | -237.82M | -121.85M |
| Net Cash (Debt) | 528.59M | 470.44M | 460.94M | 497.83M | 598.75M | 790.94M | 901.00M | 908.96M | 1.15B | 1.15B | 1.51B | 1.69B |
| Shares Outstanding | 169.19M | 161.23M | 139.47M | 139.02M | 138.89M | 138.06M | 136.96M | 136.71M | 136.59M | 135.84M | 134.78M | 134.50M |
This table shows 12 quarterly periods of Vir Biotechnology's balance sheet, from Q2 2026 back to Q3 2023, across 16 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow VIR's reporting calendar. What is a balance sheet?